Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice

Vaccine

Volumn 29, Issue 2, 2010, Pages 289-303

  Berhanu, Aklile ^a   King, David S ^a   Mosier, Stacie ^a   Jordan, Robert ^a   Jones, Kevin F ^a   Hruby, Dennis E ^a   Grosenbach, Douglas W ^a  

^a SIGA Technologies Incorporated   (United States)

Author keywords

ACAM2000; Immunodeficient mice; ST 246

Indexed keywords

IMMUNOLOGIC AGENT; SMALLPOX VACCINE; ST 246; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNODEFICIENCY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOGENICITY; IN VIVO STUDY; MOUSE; NONHUMAN; ORTHOPOXVIRUS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; VACCINATION; VACCINIA VIRUS; VIRUS STRAIN; VIRUS VIRULENCE;

ANIMALS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; BENZAMIDES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; IMMUNITY, CELLULAR; IMMUNOCOMPROMISED HOST; ISOINDOLES; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; SMALLPOX VACCINE; SURVIVAL ANALYSIS; VACCINIA VIRUS;

EID: 78649698396     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.039     Document Type: Article

References (71)

1. Fenner F., Henderson D.A., Arita I., Jezek Z., Ladnyi I.D. Smallpox and its Eradication 1988, World Health Organization, Geneva, Switzerland.
2. Amanna I.J., Slifka M.K., Crotty S. Immunity and immunological memory following smallpox vaccination. Immunol Rev 2006, 211(June):320-337.
3. Kennedy R.B., Ovsyannikova I., Poland G.A. Smallpox vaccines for biodefense. Vaccine 2009, 27(November (Suppl 4)):D73-D79.
4. Lane J.M., Ruben F.L., Neff J.M., Millar J.D. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis 1970, 122(October (4)):303-309.
5. Frey S.E., Couch R.B., Tacket C.O., Treanor J.J., Wolff M., Newman F.K., et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 2002, 346(April (17)):1265-1274.
6. Fulginiti V.A., Papier A., Lane J.M., Neff J.M., Henderson D.A. Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis 2003, 37(July (2)):251-271.
7. Cono J., Casey C.G., Bell D.M. Smallpox vaccination and adverse reactions. Guidance for cliniciens. MMWR Recomm Rep 2003, 52(February (RR-4)):1-28.
8. Bray M., Wright M.E. Progressive vaccinia. Clin Infect Dis 2003, 36(March (6)):766-774.
9. Kempe C.H. Studies smallpox and complications of smallpox vaccination. Pediatrics 1960, 26(August):176-189.
10. Rotz L.D., Dotson D.A., Damon I.K., Becher J.A. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep 2001, 50(June (RR-10)):1-25.
11. Kemper A.R., Davis M.M., Freed G.L. Expected adverse events in a mass smallpox vaccination campaign. Eff Clin Pract 2002, 5(March-April (2)):84-90.
12. Yang G., Pevear D.C., Davies M.H., Collett M.S., Bailey T., Rippen S., et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol 2005, 79(October (20)):13139-13149.
13. Duraffour S., Snoeck R., de Vos R., van Den Oord J.J., Crance J.M., Garin D., et al. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antivir Ther 2007, 12(8):1205-1216.
14. Smith S.K., Olson V.A., Karem K.L., Jordan R., Hruby D.E., Damon I.K. In vitro efficacy of ST-246 against smallpox and monkeypox. Antimicrob Agents Chemother 2009, 53(March (3)):1007-1012.
15. Chen Y., Honeychurch K.M., Yang G., Byrd C.M., Harver C., Hruby D.E. et al Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis. Virol J 2009, 6(April (1)):44.
16. Quenelle D.C., Buller R.M., Parker S., Keith K.A., Hruby D.E., Jordan R., et al. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother 2007, 51(February (2)):689-695.
17. Berhanu A., King D.S., Mosier S., Jordan R., Jones K.F., Hruby D.E., et al. ST-246 inhibits in vivo poxvirus dissemination. Virus shedding, and systemic disease manifestation. Antimicrob Agents Chemother 2009, 53(December (12)):4999-5009.
18. Huggins J., Goff A., Hensley L., Mucker E., Shamblin J., Wlazlowski C., et al. Non- human primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob Agents Chemother 2009, 53(April (6)):2620-2625.
19. Jordan R., Goff A., Frimm A., Corrado M.L., Hensley L.E., Byrd C.M., et al. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother 2009, 53(May (5)):1817-1822.
20. Grosenbach D.W., Berhanu A., King D.S., Mosier S., Jones K.F., Jordan R.A., et al. Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Proc Natl Acad Sci U S A 2010, 107(January (2)):838-843.
21. Jordan R., Tien D., Bolken T.C., Jones K.F., Tyavanagimatt S.R., Strasser J., et al. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob Agents Chemother 2008, 52(May (5)):1721-1727.
22. Jordan R., Chinsangaram J., Bolken T.C., Tyavanagimatt S.R., Tien D., Jones K.F., et al. Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246(R) following repeat oral dosing in healthy adult subjects. Antimicrob Agents Chemother 2010, 54(April (6)):2560-2566.
23. Grosenbach D.W., Jordan R., King D.S., Berhanu A., Warren T.K., Kirkwood-Watts D.L., et al. Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Vaccine 2008, 26(February (7)):933-946.
24. Silvera P.M., Peters E., Bassler J., Gong G., Lin S., Hebblewaite D., et al. Impact of concurrent ST-246 administration on ACAM2000 vaccine efficacy in cynomolgus macaques. 7th ASM Biodefense Emerging Dis Res Meet, abstr190 (H) 2009.
25. Vora S., Damon I., Fulginiti V., Weber S.G., Kahana M., Stein S.L., et al. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis 2008, 46(May (10)):1555-1561.
26. Progressive Vaccinia in a Military Smallpox Vaccinee - United States, 2009. MMWR Morb Mortal Wkly Rep 2009, 58(19):532-536. Centers for Disease Control, Prevention.
27. Human Vaccinia Infection After Contact with a Raccoon Rabies Vaccine Bait - Pennsylvania, 2009. MMWR Morb Mortal Wkly Rep 2009, 58(43):1204-1207. Centers for Disease Control, Prevention.
28. Earl P.L., Cooper N., Wyatt S., Moss B., Carroll M.W. Preparation of cell cultures and vaccinia virus stocks. Current protocols in molecular biology 1998, John Wiley and Sons, New York, p. 16.16.4-16.16.6. 2nd edn. M.F. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, K. Struhl (Eds.).
29. Chen J., Trounstine M., Alt F.W., Young F., Kurahara C., Loring J.F., et al. Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus. Int Immunol 1993, 5(June (6)):647-656.
30. Belyakov I.M., Earl P., Dzutsev A., Kuznetsov V.A., Lemon M., Wyatt L.S., et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A 2003, 100(August (16)):9458-9463.
31. Xu R., Johnson A.J., Liggitt D., Beven M.J. Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol 2004, 172(May (10)):6265-6271.
32. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938, 27(3):493-497.
33. Subrahmanyan T.P. A study of the possible basis of age-dependent resistance of mice to poxvirus diseases. Aust J Exp Biol Med Sci 1968, 46(June (3)):251-265.
34. Tscharke D.C., Woo W.P., Sakala I.G., Sidney J., Sette A., Moss D.J., et al. Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB/c mice. J Virol 2006, 80(July (13)):6318-6323.
35. Melamed S., Paran N., Katz L., Ben-Nathan D., Israely T., Schneider P., et al. Tail scarification with Vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice. Vaccine 2007, 25(November (45)):7743-7753.
36. Cummings J.F., Polhemus M.E., Hawkes C., Klote M., Ludwig G.V., Wortmann G. Lack of vaccinia viremia after smallpox vaccination. Clin Infect Dis 2004, 38(February (3)):456-458.
37. Keidan S.E., McCarthy K., Haworth J.C. Fatal generalized vaccinia with failure of antibody production and absence of serum gamma globulin. Arch Dis Child 1953, 28(April (138)):110-116.
38. Wei H., Huang D., Fortman J., Wang R., Shao L., Chen Z.W. Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox. J Virol 2009, 83(January (2)):1115-1125.
39. Payne L.G., Kristensson K. Extracellular release of enveloped vaccinia virus from mouse nasal epithelial cells in vivo. J Gen Virol 1985, 66(Pt 3):643-646. Mar.
40. Boulter E.A., Zwartouw H.T., Titmuss D.H., Maber H.B. The nature of the immune state produced by inactivated vaccinia virus in rabbits. Am J Epidemiol 1971, 94(December (6)):612-620.
41. Law M., Putz M.M., Smith G.L. An investigation of the therapeutic value of vaccinia- immune IgG in a mouse pneumonia model. J Gen Virol 2005, 86(April (4)):991-1000.
42. Vanderplasschen A., Hollinshead M., Smith G.L. Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. J Gen Virol 1997, 78(August (Pt 8)):2041-2048.
43. Miller J.D., van der Most R.G., Akondy R.S., Glidewell J.T., Albott S., Masopust D., et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008, 28(May (5)):710-722.
44. Ferrier-Rembert A., Drillien R., Meignier B., Garin D., Crance J.M. Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate. Vaccine 2007, 25(November (49)):8290-8297.
45. Amara R.R., Nigam P., Sharma S., Liu J., Bostik V. Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. J Virol 2004, 78(April (8)):3811-3816.
46. Precopio M.L., Betts M.R., Parrino J., Price D.A., Gostick E., Ambrozak D.R., et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 2007, 204(June (6)):1405-1416.
47. Harrington L.E., Most Rv R., Whitton J.L., Ahmed R. Recombinant vaccinia virus- induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J Virol 2002, 76(April (7)):3329-3337.
48. Novy P., Quigley M., Huang X., Yang Y. CD4 T cells are required for CD8 T cell survival during both primary and memory recall responses. J Immunol 2007, 179(December (12)):8243-8251.
49. Ramshaw I.A., Ramsay A.J., Karupiah G., Rolph M.S., Mahalingam S., Ruby J.C. Cytokines and immunity to viral infections. Immunol Rev 1997, 159(October):119-135.
50. Centers for Disease Control and Prevention. Smallpox Response Plan and Guidelines (Version 3.0). ; 2003. http://www.bt.cdc.gov/agent/smallpox/response-plan/index.asp.
51. Artenstein A.W., Grabenstein J.D. Smallpox vaccines for biodefense: need and feasibility. Expert Rev Vaccines 2008, 7(October (8)):1225-1237.
52. Beachkofsky T.M., Carrizales S.C., Bidinger J.J., Hrncir D.E., Whittemore D.E., Hivnor C.M. Adverse events following smallpox vaccination with ACAM2000 in a military population. Arch Dermatol 2010, 146(June (6)):656-661.
53. Berhanu A., Wilson R.L., Kirkwood-Watts D.L., King D.S., Warren T.K., Lund S.A., et al. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J Virol 2008, 82(April (7)):3517-3529.
54. Gilead. VISTIDE® (cidofovir injection). ; 1996. http://www.gilead.com/pdf/vistide.pdf.
55. Kempe C.H., Berge T.O., England B. Hyperimmune vaccinal gamma globulin; source, evaluation, and use in prophylaxis and therapy. Pediatrics 1956, 18(August (2)):177-188.
56. Edghill-Smith Y., Venzon D., Karpova T., McNally J., Nacsa J., Tsai W.P., et al. Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. J Infect Dis 2003, 188(October (8)):1181-1191.
57. Good R.A., Zak S.J., Condie R.M., Bridges R.A. Clinical investigation of patients with agammaglobulinemia and hypogammaglobulinemia. Pediatr Clin North Am 1960, 7(May):397-433.
58. Wyatt L.S., Earl P.L., Eller L.A., Moss B. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci USA 2004, 101(March (13)):4590-4595.
59. Edghill-Smith Y., Golding H., Manischewitz J., King L.R., Scott D., Bray M., et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 2005, 11(July (7)):740-747.
60. Liu L., Zhong Q., Tian T., Dubin K., Athale S.K., Kupper T.S. Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat Med 2010, 16(January (2)):224-227.
61. Sarkar J.K., Mitra A.C., Mukherjee M.K. The minimum protective level of antibodies in smallpox. Bull World Health Organ 1975, 52(3):307-311.
62. Mack T.M., Noble J., Thomas D.B. A prospective study of serum antibody and protection against smallpox. Am J Trop Med Hyg 1972, 21(March (2)):214-218.
63. Monath T.P., Caldwell J.R., Mundt W., Fusco J., Johnson C.S., Buller M., et al. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)-a second-generation smallpox vaccine for biological defense. Int J Infect Dis 2004, 8(October (Suppl 2)):S31-S44.
64. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 1992, 89(November (22)):10847-10851.
65. Norbury C.C., Malide D., Gibbs J.S., Bennink J.R., Yewdell J.W. Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo. Nat Immunol 2002, 3(March (3)):265-271.
66. Military Vaccine (MILVAX) Agency. Smallpox vaccination saftey summary: DoD smallpox vaccination program. ; 2007. http://smallpox.mil/event/spsafetysum.asp.
67. Military Vaccine (MILVAX) Agency. Smallpox Vaccination Program ; 2008. http://www.smallpox.army.mil/documents/Smallpox_QA.pdf.
68. Vaccinia virus infection after sexual contact with a military smallpox vaccinee-washington, 2010. MMWR Morb Mortal Wkly Rep 2010, 59(July (25)):773-775. Centers for Disease Control, Prevention.
69. U.S. Department of Defense. Panels find vaccines may relate to reservist's illness, death. ; 2003. http://www.defenselink.mil/releases/release.aspx%3Freleaseid=5799.
70. Kawakami Y., Tomimori Y., Yumoto K., Hasegawa S., Ando T., Tagaya Y., et al. Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum. J Exp Med 2009, 206(June (6)):1219-1225.
71. Neyts J., Leyssen P., Verbeken E., De Clercq E. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimicrob Agents Chemother 2004, 48(June (6)):2267-2273.